Treating Rett syndrome: from mouse models to human therapies

Area of Science:

• Neuroscience
• Genetics
• Metabolic Disorders

Background:

• Rare diseases present significant challenges for mechanistic study and therapy development due to limited patient populations.
• Rett syndrome (RTT) is a rare neuro-metabolic disorder caused by mutations in the methyl-CpG-binding protein 2 (MECP2) gene.

Purpose of the Study:

• To discuss Rett syndrome as a prototype for precision medicine.
• To demonstrate how mouse models contribute to understanding RTT symptom development.
• To highlight the potential of preclinical studies for improving RTT patient health.

Main Methods:

• Utilizing Mecp2-mutant mouse models for preclinical studies.
• Investigating direct targeting of the MECP2 gene.
• Exploring downstream pathways affected by MECP2 mutations.

Main Results:

• Mecp2-mutant mice provide insights into RTT pathogenesis.
• Preclinical studies are actively exploring therapeutic strategies.
• Understanding genetic and epigenetic factors (X chromosome inactivation, modifier genes) is crucial for RTT variability.

Conclusions:

• Mouse models are instrumental in advancing the understanding and treatment of Rett syndrome.
• Precision medicine approaches are essential for tailoring treatments to individual RTT patients.
• A combination of therapies may be necessary for comprehensive recovery in RTT patients.